Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

NCT02620280 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

278

Enrollment

OTHER

Sponsor class

Conditions

Invasive Ductal Breast Carcinoma

Interventions

DRUG: Carboplatin
DRUG: Abraxane
DRUG: MPDL3280A
PROCEDURE: Surgery
DRUG: Anthra

Sponsor

Fondazione Michelangelo